In vivo measurement and characterization of a novel formulation of [[177]Lu]-DOTA-octreotate
Asia Oceania Journal of Nuclear Medicine and Biology. 2016; 4 (1): 30-37
em Inglês
| IMEMR
| ID: emr-176189
ABSTRACT
Objective[s] Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" [NCA] [177]Lu. We have radiolabelled DOTA-conjugated peptide DOTA-[Tyr[3]]-octreotate with NCA 177Lu ["NCA-LuTATE"] and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body [WB] and quantitative 3D SPECT [qSPECT] [177]Lu imaging
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Compostos Organometálicos
/
Octreotida
/
Tomografia Computadorizada de Emissão de Fóton Único
/
Tumores Neuroendócrinos
/
Neoplasias Meníngeas
/
Meningioma
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Asia Oceania J. Nucl. Med. Biol.
Ano de publicação:
2016
Similares
MEDLINE
...
LILACS
LIS